Wednesday, February 15th, 2022
Registration and Dinner: 7:00 PM – 7:30 PM PT
Scientific Session: 7:30 PM – 9:00 PM PT

Learning Objectives

• Describe unmet clinical needs in the management of prostate cancer in the context of novel PSMA-directed strategies in diagnosis and management of prostate cancer
• Assess emerging clinical trial evidence on evolving PSMA-targeting strategies and its potential implications on evolving treatment paradigms in metastatic castration-resistant prostate cancer (mCRPC)
• Determine effective approaches to integrate and sequence PSMA-targeting radioligand strategies into current clinical practice to manage patients with mCRPC
• Discuss potential multidisciplinary strategies to recognize and manage toxicities associated with currently approved as well as emerging PSMA-directed therapies for mCRPC care

Thursday, February 16, 2023
Intercontinental San Francisco | 3rd floor, Grand Ballroom

Registration and Dinner: 7:00 PM - 7:30 PM PT
Scientific Session: 7:30 PM - 9:00 PM PT

Learning Objectives

• Describe the pathophysiological mechanisms underlying current/emerging therapeutic approaches for the treatment of patients with CRPC
• Assess practice-changing evidence on evolving therapeutic strategies for patients with nonmetastatic and metastatic CRPC
• Determine measures to monitor for and mitigate the impact on outcomes of treatment-related adverse events in CRPC care settings
• Apply recent guidelines and evidence from pivotal trials to inform treatment decisions among patients with CRPC across lines of care

Friday, February 17, 2023
Parc 55 San Francisco | Room: Cyril Magnin

Registration & Dinner: 6:30 PM - 7:00 PM PT
Scientific Session: 7:00 PM - 9:00 PM PT

Learning Objectives

• Evaluate the mechanistic rationale for evaluating targeted therapies, immunotherapies, and combinations to manage RCCExplain clinical evidence for the management of GU malignancies across multiple lines of care
• Assess the implications of recent trial data on novel therapies and combinations in the context of evolving treatment paradigms for high-risk, advanced/metastatic, and early-stage RCC
• Determine effective strategies for the identification and management of treatment-related toxicities among patients who receive care for RCC
• Devise personalized care plans for RCC by incorporating methods to stratify risk, clinical trial evidence, and patient- and tumor-specific characteristics

Friday, February 17, 2023
W San Francisco | Great Room

Registration & Dinner: 7:00 PM - 7:30 PM PT
Scientific Session: 7:30 PM - 9:00 PM PT

Learning Objectives

• Explain the pathophysiological mechanisms of CDK4/6 dysregulation in prostate cancer and rationale underlying their inhibition in advanced CSPC and CRPC
• Assess study design and clinical updates on CDK4/6 inhibitors investigated for the treatment of patients with advanced CSPC and CRPC
• Evaluate evidence from pivotal trials on CDK4/6 inhibitors within the context of evolving therapeutic strategies for patients with advanced prostate cancer
• Develop proactive strategies to monitor and mitigate adverse events associated with CDK4/6 inhibitors evaluated in patients with prostate cancer